5-chloro-2-(4-methyl-1-piperazinyl)benzoxazole | 199292-65-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-chloro-2-(4-methyl-1-piperazinyl)benzoxazole
• 英文别名: 5-chloro-2-(4-methylpiperazin-1-yl)-1,3-benzoxazole
• CAS: 199292-65-4
• 化学式: C₁₂H₁₄ClN₃O
• 分子量: 251.716
• InChiKey: YYMDUZXCAZEQCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  32.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-chloro-2-(4-methyl-1-piperazinyl)benzoxazole 、 丙烯酰碘 在 氯仿 、 甲醇 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以to obtain the title compound (36 mg) in light yellow color的产率得到1-allyl-1-methyl-4-(5-chlorobenzoxazol-2-yl)piperazinium iodide
  参考文献：
  名称：

  Serotonin 5-HT3 receptor partial activator

  摘要：

  本发明提供了一种5-HT3受体部分激活剂，其具有5-HT3受体激活作用，除了其5-HT3受体拮抗作用外，不会引起便秘等副作用。特别地，基于新合成的苯并噁唑衍生物的发现，其以以下式（2）的化合物为代表，具有强烈的5-HT3受体拮抗作用和5-HT3受体激活作用，本发明提供这些苯并噁唑衍生物作为5-HT3受体部分激活剂。在上述式中，R1到R4可以相同或不同，每个代表氢原子，卤原子，取代或未取代的低级烷基，取代或未取代的低级烯基或取代或未取代的氨基，或R1和R2的两个基团可以连接在一起形成环结构，即苯环；R5表示氢原子，取代或未取代的低级烷基或取代或未取代的低级烯基；m为1至4的整数。

  公开号：

  US06333328B1
• 作为产物：
  描述：

  4-氯-2-硝基苯酚 在 palladium on activated charcoal 氢氧化钾 、 五氯化磷 、 氢气 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 1.5h， 生成 5-chloro-2-(4-methyl-1-piperazinyl)benzoxazole
  参考文献：
  名称：

  Regulatory molecules for the 5-HT3 receptor ion channel gating system

  摘要：

  Substituted benzoxazole derivatives which possess a nitrogen containing heterocycle at C2 are selective partial agonists of the 5-HT3 receptor. Alteration of substituents on the benzoxazole nucleus affords both agonist-like and antagonist-like compounds, and uniquely modifies the function of the 5-HT3 receptor ion channel gating system. SAR and corroborative computational docking study for these partial agonists successfully explained structure and function of the 5-HT3 receptor. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.02.054

文献信息

• [EN] TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES<br/>[FR] COMPOSÉS DE TÉTRAHYDROBENZOFURO[2,3-C]PYRIDINE ET DE BÊTA-CARBOLINE POUR LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION DE TROUBLES ASSOCIÉS À DES AGRÉGATS DE PROTÉINE TAU
  申请人：AC IMMUNE SA

  公开号：WO2019233883A1

  公开（公告）日：2019-12-12

  The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

  本发明涉及一种可以用于治疗、缓解或预防与Tau（微管相关单元）蛋白聚集相关的一组疾病和异常的新化合物（I）的公式。这些疾病和异常包括但不限于神经原纤维缠结（NFTs），如阿尔茨海默病（AD）。
• A New 5-HT3 Receptor Ligand. II. Structure-Activity Analysis of 5-HT3 Receptor Agonist Action in the Gut.
  作者：Megumi YAMADA、Yasuo SATO、Kazuko KOBAYASHI、Fukio KONNO、Tomoko SONEDA、Takashi WATANABE

  DOI：10.1248/cpb.46.445

  日期：——

  Several modified 2-piperazinyl benzoxazole derivatives, which exhibit an agonistic effect on gastrointestinal motility, were synthesized and their effects on the contraction of guinea-pig ileum were examined. The quaternary piperazinyl benzoxazole structure has a restricted conformation and stereostructure compared to those of the other 5-HT3 receptor agonists, serotonin and meta-chlorophenylbiguanide. The mutual positions of the aromatic ring, nitrogen atom and terminal amine are considered to form the pharmacophore of the 5-HT3 receptor agonist in the gut. In the serotonin-evoked reflex bradycardia [Bezold-Jarisch (B-J) reflex] inhibition test using rats the B-J reflex-inducing ratio was different for each synthesized compound. These results suggest that, in these 5-HT3 receptor agonists, the substituents of the benzoxazole ring influence the B-J reflex-inducing activity in rats.

  合成了几种对胃肠道蠕动具有兴奋作用的2-哌嗪基苯并噁唑衍生物，并研究了它们对豚鼠回肠收缩的影响。与5-HT3受体激动剂5-羟色胺和邻氯苯基双胍相比，季铵哌嗪基苯并噁唑结构具有受限的构象和立体结构。苯环、氮原子和末端胺的相对位置被认为是形成肠道5-HT3受体激动剂的药效团。在用大鼠进行的阻断血清素诱发反射性心动过缓[Bezold-Jarisch(B-J)反射]的试验中，每个合成化合物的诱发B-J反射的比例是不同的。这些结果表明，在这些5-HT3受体激动剂中，苯并噁唑环的取代基会影响大鼠的诱发B-J反射活性。
• [EN] 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE 1,3,4,5-TÉTRAHYDRO-2H-PYRIDO[4,3-B]INDOLE POUR LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION DE TROUBLES ASSOCIÉS À DES AGRÉGATS DE TAU COMME LA MALADIE D'ALZHEIMER
  申请人：AC IMMUNE SA

  公开号：WO2019134978A1

  公开（公告）日：2019-07-11

  The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

  本发明涉及一类新化合物，可用于治疗、缓解或预防与Tau蛋白聚集相关的一组疾病和异常，包括但不限于神经原纤维缠结（NFTs），如阿尔茨海默病（AD）。
• Serotonin 5-HT, receptor partial activator
  申请人：——

  公开号：US20010016579A1

  公开（公告）日：2001-08-23

  This invention provides a serotonin 5-HT 3 receptor partial activator which has a serotonin 5-HT 3 receptor activating action, in addition to its serotonin 5-HT 3 receptor antagonism, and does not cause constipation as a side effect. Particularly, based on the finding that newly synthesized benzoxazole derivatives typified by the compounds of the following formula (2) have strong serotonin 5-HT 3 receptor antagonism and serotonin 5-HT 3 receptor activating action, this invention provides these benzoxazole derivatives as serotonin 5-HT 3 receptor partial activators. 1 In the above formula, R 1 to R 4 may be the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R 1 and R 2 may be linked together to form a ring structure, namely benzene ring; R 5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted lower alkenyl group; and m is an integer of 1 to 4.

  本发明提供了一种5-HT3受体部分激动剂，该激动剂具有5-HT3受体激活作用，除了其5-HT3受体拮抗作用外，不会引起便秘等副作用。特别是，基于新合成的苯并咪唑衍生物发现，该衍生物以以下式子（2）的化合物为代表具有强烈的5-HT3受体拮抗作用和5-HT3受体激活作用，本发明提供这些苯并咪唑衍生物作为5-HT3受体部分激动剂。在上述公式中，R1到R4可以相同也可以不同，每个表示氢原子、卤素原子、取代或未取代的低级烷基、取代或未取代的低级烯基或取代或未取代的氨基；或R1和R2的两个基团可以连接在一起形成环结构，即苯环；R5表示氢原子、取代或未取代的低级烷基或取代或未取代的低级烯基；m是1到4的整数。
• Serotonin 5-HT3 receptor partial activator
  申请人：MEIJI SEIKA KAISHA, LTD.

  公开号：US20030013730A1

  公开（公告）日：2003-01-16

  This invention provides a serotonin 5-HT 3 receptor partial activator which has a serotonin 5-HT 3 receptor activating action, in addition to its serotonin 5-HT 3 receptor antagonism, and does not cause constipation as a side effect. Particularly, based on the finding that newly synthesized benzoxazole derivatives typified by the compounds of the following formula (2) have strong serotonin 5-HT 3 receptor antagonism and serotonin 5-HT 3 receptor activating action, this invention provides these benzoxazole derivatives as serotonin 5-HT 3 receptor partial activators. 1 In the above formula, R 1 to R 4 may be the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R 1 and R 2 may be linked together to form a ring structure, namely benzene ring; R 5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted lower alkenyl group; and m is an integer of 1 to 4.

  该发明提供了一种5-HT3受体部分激动剂，具有5-HT3受体激活作用，除了5-HT3受体拮抗作用外，不会引起便秘等副作用。特别地，基于新合成的苯并噁唑衍生物的发现，该衍生物以以下公式（2）的化合物为代表，具有强烈的5-HT3受体拮抗作用和5-HT3受体激活作用，该发明提供这些苯并噁唑衍生物作为5-HT3受体部分激动剂。在上述公式中，R1至R4可以相同或不同，每个代表氢原子、卤素原子、取代或未取代的低级烷基、取代或未取代的低级烯基或取代或未取代的氨基，或R1和R2的两个基团可以连接在一起形成环结构，即苯环；R5代表氢原子、取代或未取代的低级烷基或取代或未取代的低级烯基；m是1到4的整数。